KONEXElectrical Equipment332190

OceansBio

₩2,000 0.00%2026-11-18 close
Market Cap
₩3B
Turnover
₩0
Volume
0 shares
Shares out.
1.5M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

A loss-widening electroceutical developer

With 2025 revenue of KRW 102.18 million and a wider operating loss, OceansBio has relied on repeated third-party share placements in 2026 to fund its electroceutical pipeline.

  1. 1

    2025 revenue was KRW 102.18 million, down 47.31% from 2024 (based on financial data).

  2. 2

    The 2025 operating loss widened to KRW 2.98 billion from KRW 1.92 billion in 2024.

  3. 3

    The third-party share placement disclosed on November 6, 2026 was priced at KRW 13,000, a 549.35% premium to the reference price.

  4. 4

    The product pipeline is widening from epilepsy toward depression and sleep disorders, alongside a planned overseas base in Yantai, China.

  5. 5

    The share price ranged widely, with a 52-week low of KRW 870 on March 9, 2026 and a 52-week high of KRW 7,930 as of October 21, 2026.

02

Business structure

OceansBio was founded in July 2018 as an electroceutical developer headquartered in Changwon, South Gyeongsang Province. Its core technology applies mild electrical stimulation to the vagus nerve in the neck to control epileptic seizures.

Products split into an implantable vagus nerve stimulator (iVNS) and a transcutaneous auricular device (taVNS) that stimulates through the ear. The company says its AI detects pre-seizure signs and stimulates only when needed, which it argues keeps battery drain low.

Its product strategy extends indications from epilepsy toward depression and sleep disorders. A December 2025 report said a sleep-wellness product, BeCozU, was planned for launch by the end of 2025, and three new depression-focused products were to roll out from 2026.

The company describes itself as the only domestic developer of epilepsy electroceuticals, a self-description. Overseas, an August 2025 report said it signed an MOU with Shandong Hengguang Biotech for TaVNS supply worth KRW 1 billion a year and set up a local subsidiary in Yantai, China.

In the United States it has worked with a New York senior-care operator on a cognitive training solution and reported a Manhattan branch.

03

Recent trends

Based on disclosed financials, 2024 revenue was KRW 19.39 million, the operating loss was KRW 1.92 billion and the net loss was KRW 1.44 billion. In 2025 revenue fell to KRW 102.18 million, down 47.31% year on year, while the operating loss widened to KRW 2.98 billion.

The net loss reached the KRW 2 billion range, and operating cash flow also recorded a deficit in the KRW 2 billion range. As of December 31, 2025, the equity ratio was 13.02% and the debt dependence ratio was 60.05%, both weaker than at end-2024.

Funding began with a convertible redeemable preferred share issuance disclosed on March 19, 2026, raising KRW 899.997 million at KRW 10,500 per share.

On November 6, 2026 the company decided on a third-party placement of 46,153 shares at KRW 13,000, raising KRW 599.989 million in operating funds with payment due November 16, 2026. Proceeds are earmarked for electroceutical R&D and operations, with planned uses of KRW 200 million in 2026 and KRW 200 million in 2027.

The 52-week high and low as of October 21, 2026 were KRW 7,930 and KRW 870, and TradingView data show a 52.10% decline over the past year. The stock closed at KRW 1,900 on November 6, down 5% from the prior session, and the current price at drafting is KRW 2,000. A shareholder report filed April 1, 2026 showed Capstone Partners holding 10.07%.

04

Outlook

The key variable for future results is how quickly revenue moves from development into product sales. In a November 2024 report, the company set targets of a KOSDAQ listing in 2026 and revenue of KRW 12.5 billion in 2027.

As of November 2026 it remains a KONEX-listed company, and its 2025 revenue of KRW 102.18 million leaves a large gap to that target. On the product side, the launch of BeCozU and the staggered rollout of three depression-focused products are the next checkpoints.

Overseas, the revenue contribution of the Yantai subsidiary and progress on U.S. FDA and other approvals are the key variables. The company has stated a goal of licensing its technology to global medical device makers after approvals.

On the capital side, conversion rights become exercisable from November 17, 2026, and the minimum adjusted conversion price of KRW 9,100 will shape dilution if the share price falls. The redeemable preferred shares carry a 6% annual interest component on repayment, so the financial burden accumulates over time.

Whether further share issuances occur and how the operating loss changes will be visible in the 2026 annual results disclosure.

05

Bull factors

Indication expansion pipeline

The company has outlined a plan to extend its products from epilepsy into depression and sleep disorders. A December 2025 report said the sleep-wellness product BeCozU was slated for launch by the end of 2025, with three new products to roll out from 2026. It also said it would add AI-based therapeutic functions.

Early overseas footholds

An August 2025 report said the company signed an MOU with Shandong Hengguang Biotech for TaVNS supply worth KRW 1 billion a year and set up a subsidiary in Yantai. In New York it plans to apply a cognitive training solution through a senior-care operator. The company said it aims to license its technology to global device makers after approvals.

Public support and external recognition

An August 2025 report said the company was selected for the Ministry of SMEs and Startups' Scale-up TIPS program, securing up to KRW 1.2 billion in R&D funding.

In December 2025 it received a Prime Minister's Award at the 2025 Venture Startup Promotion Awards, with core technology and patent value cited among the criteria. These recognitions relate to public support and awards, separate from commercial sales performance.

06

Bear factors

Thin revenue base

2025 revenue was KRW 102.18 million, down 47.31% from 2024. Measured against the KRW 12.5 billion revenue target for 2027 that the company cited in a November 2024 report, the gap is very large. The slow pace at which commercialization converts into revenue remains the business's most visible weakness.

Widening losses and cash burn

Alongside the larger operating loss, operating cash flow also posted a deficit in the KRW 2 billion range, meaning the operating loss flowed through to cash outflows. Over the same period the equity ratio fell to 13.02% and the debt dependence ratio reached 60.05%.

Dilution and conversion terms

The March 2026 shares carry a conversion price of KRW 10,500 and the November 2026 shares were issued at KRW 13,000. The minimum adjusted conversion price is KRW 7,350 for the March shares and KRW 9,100 for the November shares.

Repayment carries a 6% annual interest component on the issue price, so share count growth and financial burden can both be raised.

07

Risk factors

Market and trading

TradingView data show a daily volatility of 16.83%, which is high. KONEX trading volume is small, so a few transactions can move the price sharply. Venture funding conditions are sensitive to interest rates and investor sentiment, which can affect the terms of future share issuances.

Regulatory and approval

The company has said taVNS products must secure certification through medical device safety verification and frequency and current pulse testing. Specific timelines for U.S. FDA and other overseas approvals are not set out in the public material.

Launch timing and indication expansion for new products may depend on approvals and additional clinical results.

Commercialization and overseas execution

In a November 2024 report the company said it expects the electroceutical market to reach KRW 60 trillion by 2029. That figure is a company projection, so whether market growth translates into revenue remains a execution risk.

The China arrangement is still at MOU stage, and how quickly the Yantai subsidiary contributes to revenue is an open variable.

08

Overall view

OceansBio develops vagus nerve stimulation electroceuticals for epilepsy. Its technology, indication expansion plans, overseas steps, and public support and awards are the main strengths.

On the other side, 2025 revenue stayed in the KRW 100 million range while both operating and net losses widened, and the financial structure weakened compared with end-2024.

The convertible redeemable preferred share issuances and third-party placements in 2026 provided funds but also bring share count growth and financial burden. The share price moved sharply between a 2026 low of KRW 870 and a 52-week high of KRW 7,930, and small KONEX trading volume keeps volatility high.

The product launches and overseas plans the company has outlined have not yet appeared as a clear revenue contribution in the 2025 disclosed results. Taken together, the technology and business plans are concrete, while the results and financial indicators still reflect an early commercial stage.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 13 more articles and sources
  1. digitaltoday.co.kr
  2. m.news.nate.com
  3. news.nate.com
  4. jobkorea.co.kr
  5. markets.hankyung.com
  6. kr.tradingview.com
  7. etnews.com
  8. venturesquare.net
  9. v.daum.net
  10. mt.co.kr
  11. tmc.pusan.ac.kr
  12. news2day.co.kr
  13. oceansbio.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis